Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business UpdateGlobeNewsWire • 08/09/22
Wall Street Analysts Predict a 169% Upside in Prelude Therapeutics Incorporated (PRLD): Here's What You Should KnowZacks Investment Research • 06/22/22
Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations UpdateGlobeNewsWire • 05/10/22
Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare ConferenceGlobeNewsWire • 03/11/22
Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual MeetingGlobeNewsWire • 03/09/22
Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/11/22
Prelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual ConferenceGlobeNewsWire • 01/04/22
Prelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/23/21
Prelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations UpdateGlobeNewsWire • 11/12/21
Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 InhibitorGlobeNewsWire • 11/08/21
Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/07/21
Prelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations UpdateGlobeNewsWire • 08/12/21
Prelude Therapeutics Announces First Quarter 2021 Financial Results and Operations UpdateGlobeNewsWire • 05/11/21
Prelude Therapeutics Announces Participation at Three Upcoming Virtual Investor ConferencesGlobeNewsWire • 03/03/21
Prelude Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 01/11/21
Prelude Therapeutics Announces Dosing of First Patient in Phase 1 Trial of MCL1 Inhibitor PRT1419 for the Treatment of Relapsed/Refractory Hematologic MalignanciesGlobeNewsWire • 09/30/20
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 09/29/20
U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO WeekSeeking Alpha • 09/26/20